A New Natural Compound Drug of Treatment of Type 2 Diabetes: Whether May Stop Administration of Any Drugs by Oral or Injection After Administered It or Not?

Gang Shu; Fengling Yao
June 2007
Diabetes;Jun2007 Supplement 1, Vol. 56, pA576
Academic Journal
So far, there have a lot of drugs can treatment of type 2 diabetes in the world, but have not any drugs can complete cure type 2 diabetes. Patients will oral or inject administration of drugs for life. We find one natural compound, it is called N-gs6 as code name, it has effect to reduce blood glucose, and may it have a potential ability to complete cure the type 2 diabetes. In regards to the testing, type 2 diabetes was induced in male Wistar rats by a single dose of STZ(60mg/kg). 5 days later, after verifying that blood sugar level was sufficiently high, the test material N-gs6 was administered for 7 days. Wistar rats (n= 10) were intubated with N-gs6 (0, 1.2g/kg body weight with drug) daily. The glucose of treated rats was 19.39±6.064 (mmol/L) compared to 27.14±1.154 (mmol/L) for the untreated diabetic rate (n=10, P<0.01). The research found that evidence is clear the compound reduce blood glucose when administered to rats by orally. N-gs6 has extremely low toxicity, LD50 for 6.5g/kg, its high biological safety are suitable for oral use. Later, the N-gs6 showed some unusual character in a clinic of less in amount. It not only reduce glucose but also can treatment of postprandial hypoglycemia; Peak value of glucose lingered of some patients from 1.25h back to 0.75h gradually; its effect is strong and balanced; Surprisingly, part of patients can stop any drugs orally at lunch and dinner intermittently after oral administration of N-gs6, but still do not stop drug by oral at breakfast now. One interpretation would be that the natural compound drug is new agent which with different mechanisms of action comparing other drugs. It is guess that a reflex or contact should be established along with time-lapse, patients with type 2 diabetes may stop administration of any drugs after administration of N-gs6 orally for a long-term.


Related Articles

  • Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Dailey, George; Rosenstock, Julio; Moses, Robert G.; Ways, Kirk // Diabetes Care;Oct2004, Vol. 27 Issue 10, p2363 

    Objective: Insulin glulisine is a novel analog of human insulin designed for use as a rapid-acting insulin. This study compared the safety and efficacy of glulisine with regular human insulin (RHI) in combination with NPH insulin.Research Design and Methods: In total,...

  • Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine. RIDDLE, MATTHEW C.; FORST, THOMAS; ARONSON, RONNIE; SAUQUE-REYNA, LEOBARDO; SOUHAMI, ELISABETH; SILVESTRE, LOUISE; LIN PING; ROSENSTOCK, JULIO // Diabetes Care;Sep2013, Vol. 36 Issue 9, p2497 

    OBJECTIVE--When oral therapy for type 2 diabetes is ineffective, adding basal insulin improves glycemic control. However, when glycated hemoglobin (HbA1c) remains elevated because of postprandial hyperglycemia, the next therapeutic step is controversial. We examined the efficacy and safety of...

  • HYPOGLYCEMIC AGENTS, ORAL.  // Davis's Drug Guide for Nurses, 10th edition;2007, p616 

    The article presents a nursing guide for several oral hypoglycemic agents, including glimepiride, glipizide, and glyburide, drugs used for controlling blood glucose in patients with non-insulin-dependent diabetes mellitus. The mechanism of action of the drug is discussed. Information on its...

  • Intensive blood glucose control for type 2 diabetes: meta-analysis.  // Africa Health;Mar2012, Vol. 34 Issue 3, p59 

    The article reports on a meta-analysis of intensive blood glucose control for type 2 diabetes, which found that intensive control could not minimize all-cause mortality, however, can increase the risk of severe hypoglycaemia by about 30%.

  • Medication and Exercise Interactions: Considering and Managing Hypoglycemia Risk. Shahar, Jacqueline; Hamdy, Osama // Diabetes Spectrum;Winter2015, Vol. 28 Issue 1, p64 

    The article discusses medication management considerations in people with diabetes who are engaged in exercise, with dependence on antihyperglycemic medications. Topics discussed, include additive pathways to stimulate glucose uptake by muscles via translocation of glucose transport proteins,...

  • Adherence to the Standard Guidelines for Prescription of Antidiabetic Agents in Patients with Type 2 DM. Alhadidi, Qasim M.; Sahib, Ahmed S.; Jaffer, Ali M.; Ismael, Maha H.; Hassan, Ekhlas K.; Shareef, Saja M.; Shoesh, Asmaa M.; Dawood, Asia S. // Journal of Applied Pharmaceutical Science;Jul2012, Vol. 2 Issue 7, p1 

    Prescription of appropriate antihyperglycemic agent depending on the standard guidelines has an important role in controlling diabetes and improving patient health. The aim of the present prospective study is to follow-up the adherence of prescribers to the standard guidelines for the...

  • Insulin Treatment of Fasting or Postprandial Glucose in Type 2 Diabetes. Does It Matter? The South Danish Diabetes Study (SDDS). Henriksen, Jan Erik; Gram, Jeppe; Beck-Nielsen, Henning // Diabetes;Jun2007 Supplement 1, Vol. 56, pA51 

    Insulin treatment of fasting hyperglycaemia using bedtime NPH insulin is often used in Type 2 diabetes whereas treatment of postprandial hyperglycaemia has not gained much impact. This investigator driven, randomised, intention to treat (ITT), and treat to target study compared the effect of NHP...

  • Administrative Claims Analysis of New Exenatide Patients with Type 2 Diabetes. Wade, Ron; Quimbo, Ralph; Barron, John; Schroeder, Brock; Wintle, Matthew; Misurski, Derek; Oglesby, Alan // Diabetes;Jun2007 Supplement 1, Vol. 56, pA561 

    Traditional antidiabetic therapies often fail to maintain glycemic control over time. In this retrospective analysis using a large, national commercial health care claims database, we describe baseline characteristics, comorbidities, and concomitant therapies in patients prescribed exenatide in...

  • Treatment of type 2 diabetes. Nazarko, Linda // British Journal of Healthcare Assistants;Mar2010, Vol. 4 Issue 3, p124 

    When a person has been diagnosed with type 2 diabetes, treatment aims to maintain normoglycaemia (blood sugar within normal limits), relieve the symptoms of diabetes, maintain or improve quality of life and prevent the complications associated with diabetes, such as stroke, heart attack, eye and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics